Leap Therapeutics' anti-DKK1 antibody in combination with BeiGene's anti-PD-1 antibody demonstrated clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients. More news from Eluminex Bio, CTTQ, Neurophth, BeiGene and the CDE.
Innovent Biologics is licensing the Greater China rights to up to three enzyme-specific inhibitors from Amagma Therapeutics to strengthen its inflammatory disease portfolio. More news from Pharbers, BioTroy, Biocytogen, Neukio and Hengrui Pharma.
Mabwell is the 13th pre-revenue biotech startup listed on STAR. It raised RMB3.477 billion ($547 million) with an offer price of RMB34.8 apiece. It opened at RMB32 then further dropped to RMB24.5 to end the day.
Abbisko Therapeutics has inked a pact with Eli Lilly to develop and commercialise novel molecules against an undisclosed target for cardiometabolic diseases. More news from ReviR Therapeutics, Leman and SparX Bio.
CStone's study provides the only anti-PD-L1 immunotherapy plus chemotherapy option for squamous NSCLC patients worldwide. More news from Junsai, Gracell, BeyondSpring, HISUN, EastChina, Shenogen and Betta.
Several big series A financing in December warrant attention, as they speak of a wider trend for drug innovation in China. Big pharmaceutical companies are sharing risks, and scientists are creating a mRNA platform.
Chinese biotech startups Belief Biomed is one of the few gene therapy players with in-house manufacturing capabilities, and Regor is able to deliver one preclinical candidate in 10 months with its rCARD platform.